新型コロナウイルス感染症の影響によるIVD(体外診断)の世界市場予測:技術別(PCR、NGS、ELISA、迅速検査、血液学、止血、臨床化学、微生物学検査、尿検査)、エンドユーザー別、地域別

◆英語タイトル:COVID 19 Impact on IVD (In Vitro Diagnostics) Market by Technology (PCR, NGS, ELISA, Rapid Test, Hematology, Hemostasis, Clinical Chemistry, Microbiology Testing, Urinalysis), End-user and Region - Global Forecast to 2025
◆商品コード:MD 7631
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年5月20日
◆ページ数:93
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥691,600見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥847,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

MarketsandMarkets社は新型コロナウイルス感染症の影響によるIVD(体外診断)の世界市場が2022年610億ドルから2025年まで、年平均6.5%成長すると予測しています。本調査レポートでは、新型コロナウイルス感染症の影響によるIVD(体外診断)の世界市場を詳細に調査・分析し、IVD診断産業システム、産業インサイト、新型コロナウイルス感染症影響によるIVD診断市場評価、エンドユーザー別(病院ベース検査室、独立型実験室、実験室参考文献、ケアポイント&セルフテスト、研究者&アカデミア、その他)、国家別 、競争状況、主要産業使用事例などを含め、ご提供いたします。
・IVD診断産業システム
・産業インサイト
・新型コロナウイルス感染症の影響によるIVD診断市場評価
・IVD診断の世界市場:エンドユーザー別(病院ベース検査室、独立型実験室、実験室参考文献、ケアポイント&セルフテスト、研究者&アカデミア、その他)
・新型コロナウイルス感染症の影響によるIVD診断市場 :国家別
・競争状況
・主要産業使用事例
【レポートの概要】

“The global in-vitro diagnostics market is expected to be valued at USD 61.0 billion in 2020, growing at a CAGR of 6.5% during 2020-2025.”
The global in-vitro diagnostics market size is expected to be valued at USD 61.0 billion in 2020, growing at a CAGR of 6.5% during 2020-2025. The demand for in-vitro diagnostic products due to the COVID-19 pandemic is expected to increase mainly due to factors such as a sharp rise in market demand for PCR, NGS, serology based rapid-test products, the supportive regulatory landscape for product development & commercialization, and a sharp rise in target patient population. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities as well as to focus on product commercialization & upgrades. The in-vitro diagnostics market is segmented on technology, end user, and region/country.

“The PCR segment is expected to hold the largest share of the market in 2020 H1.”
Based on technology, the in-vitro diagnostics market is segmented into PCR, NGS, ELISA, Rapid-tests, clinical chemistry, hematology, hemostasis, urinalysis, microbiology testing, and others. The PCR segment is expected to hold the largest share of the global in-vitro diagnostics industry in 2020 – H1. Factors such as the increasing patient emphasis on effective & early patient screening, continued commercialization of novel COVID screening platforms by major players, early efforts of key players to address supply chain bottlenecks, and easy availability of controls & standards are driving the growth of this segment.

“US to account for the largest share of the in-vitro diagnostics industry in 2020 H1.”
The US is expected to account for the largest share of the in-vitro diagnostics market in 2020 – H1, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative diagnostic products coupled with ongoing advancements in the field of gene & immunoassay based products, the recent discovery of genetic biomarkers & their clinical role in immunoassay testing, supportive government policies & their emphasis on novel product development, and the significant expansion of target patient population.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 (45%), Tier 2 (34%), and Tier 3 (21%)
• By Designation: C-level (47%), Director-level (33%), and Others (20%)
• By Region: North America (35%), Europe (32%), APAC (25%), Latin America (6%), and MEA (2%)

As of 2019, some of the prominent players in the in-vitro diagnostics market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Biomerieux (France), and QIAGEN (Germany), among others.

Research Coverage
This report studies the in-vitro diagnostics market based on technology, end user, and region/country. It studies major factors (such as drivers and restraints) affecting the market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for global leaders. It analyzes micromarkets with respect to individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis — industry trends, COVID impact on major technologies, market shares of major global players, which together form basic views. It also analyzes the competitive landscape; major & emerging segments of the in-vitro diagnostics market; and high-growth geographies and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING MARKET ESTIMATION
2.2.2 PROCEDURE BASED BASED MARKET ESTIMATION
2.2.3 PRIMARY DATA VALIDATION
2.3 COVID-19 IMPACT ASSESSMENT METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS

3 IN VITRO DIAGNOSTICS INDUSTRY ECOSYSTEM
3.1 MAJOR TECHNOLOGIES
3.2 KEY APPLICATION AREAS
3.3 PROMINENT END USER CATEGORIES
3.4 50 MAJOR GLOBAL MANUFACTURERS

4 IN VITRO DIAGNOSTICS: INDUSTRY INSIGHTS
4.1 MARKET DYNAMICS
4.1.1 DRIVERS
4.1.2 RESTRAINTS
4.1.3 OPPORTUNITIES
4.1.4 CHALLENGES
4.2 GLOBAL REGULATORY SCENARIO
4.3 GLOBAL SUPPLY CHAIN ASSESSMENT

5 IN VITRO DIAGNOSTICS MARKET ASSESSMENT FOR COVID IMPACT, BY TECHNOLOGY [USD MILLION; 2019, 2020 (H1), 2020 (H2), 2021, 2025]
5.1 POLYMERASE CHAIN REACTION (PCR)
5.2 NEXT GENERATION SEQUENCING (NGS)
5.3 MICROARRAY
5.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION (INAAT)
5.5 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
5.6 LATERAL FLOW ASSAY
5.7 HEMATOLOGY
5.8 HEMOSTASIS
5.9 URINANALYSIS
5.10 MICROBIAL TESTING
5.11 CLINICAL CHEMISTRY
5.12 OTHER TECHNOLOGIES

6 IN VITRO DIAGNOSTICS: END USER LANDSCAPE
6.1 HOSPITAL-BASED LABORATORIES
6.2 INDEPENDENT LABORATORIES
6.3 REFERENCE LABORATORIES
6.4 POINT-OF-CARE AND SELF TESTING
6.5 RESEARCHERS & ACADEMIA
6.6 OTHER END USERS

7 IN VITRO DIAGNOSTICS MARKET ASSESSMENT FOR COVID IMPACT, BY COUNTRY [USD MILLION; 2019, 2020 (H1), 2020 (H2), 2021, 2025]
7.1 US
7.2 GERMANY
7.3 UK
7.4 FRANCE
7.5 ITALY
7.6 SPAIN
7.7 CHINA
7.8 JAPAN
7.9 INDIA
7.10 SOUTH KOREA
7.11 AUSTRALIA
7.12 REST OF AMERICAS
7.13 REST OF EUROPE
7.14 REST OF ASIA-PACIFIC
7.15 MIDDLE EAST AND AFRICA

8 COMPETITIVE LANDSCAPE
8.1 OVERVIEW
8.2 MARKET SHARE OF TOP 5 VENDORS (IN TERMS OF %REVENUE, AS OF 2019)
8.3 PRODUCT PORTFOLIO OF MAJOR VENDORS FOR COVID DIAGNOSTICS
8.4 RECENT STRATEGIC INITIATIVES (DURING DECEMBER 2019 – MARCH 2020)
8.4.1 PORTFOLIO DIVERSIFICATION
8.4.2 INVESTMENTS AND FUNDINGS
8.4.3 PRODUCT DEVELOPMENT PARTNERSHIPS
8.4.4 STRATEGIC COLLABORATIONS

9 MAJOR INDUSTRY USE CASES
9.1 IN VITRO DIAGNOSTIC VENDORS
9.2 ADJACENT INDUSTRY VENDORS
9.3 RAW MATERIAL AND COMPONENT SUPPLIERS
9.4 HEALTHCARE SOFTWARE PROVIDERS



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[新型コロナウイルス感染症の影響によるIVD(体外診断)の世界市場予測:技術別(PCR、NGS、ELISA、迅速検査、血液学、止血、臨床化学、微生物学検査、尿検査)、エンドユーザー別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆